With the PDUFA date for Johnson & Johnson's (JNJ 0.01%) SGLT-2 inhibitor Invokana just around the corner, the FDA will soon deliberate on another Type 2 diabetes drug that belongs to the same class: Eli Lilly's (LLY 0.01%) empagliflozin. Can these drugs get the green light, or will the FDA require both companies to run more clinical trials? Is the FDA's rejection of Forxiga, an SGLT-2 inhibitor developed by Bristol-Myers Squibb (BMY +0.02%) and AstraZeneca (NYSE: AZN), a signal that these drugs will face an uphill battle during the approval process? Health-care analyst Max Macaluso discusses these topics in the following video.
SGLT-2 inhibitors could become a new option for Type 2 diabetics -- but the FDA has to approve them first..
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo